Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review

Figures & data

Table 1 Safety Profile of Lasmiditan, Ubrogepant and Rimegepant Available from Published Trials

	Lasmiditan	Ubrogepant	Rimegepant
Target	5-HT1F receptors	CGRP receptor	CGRP receptor
Formulation	Oral tablet	Oral tablet	Oral tablet
Dosage	50, 100 and 200 mg	50 and 100 mg	75 mg
Most common treatment-emergent adverse events	Dizziness	Dizziness	Dizziness
	Fatigue	Nausea	Nausea
	Nausea	Somnolence	Urinary tract infection
	Paraesthesia
	Somnolence
Treatment-related serious adverse events	Serotonin syndrome (n = 1)^Citation23	Seizure (n = 1)^Citation34	None
	Driving impairment up to 8 hours after dosing^Citation28	Sinus tachycardia (n = 1)^Citation36

Figure 1 Mean percentage of treatment-emergent adverse events (AEs) of lasmiditan,^18–20 ubrogepant^32–34 and rimegepant^45–47 from available clinical studies.

Figure 2 Mean percentage of treatment-related adverse events (AEs) of lasmiditan,^18–20 ubrogepant^32–34 and rimegepant^45–47 from available clinical studies.

Ashina M, Reuter U, Smith T, et al. Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia. 2021;41(3):294–304. doi:10.1177/0333102421989232

 PubMed Web of Science ®Google Scholar

Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–2241. doi:10.1056/NEJMoa1813049

 PubMed Web of Science ®Google Scholar

Pearlman EM, Wilbraham D, Dennehy EB, et al. Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol. 2020;35(5):e2732. doi:10.1002/hup.2732

 PubMed Web of Science ®Google Scholar

Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60(1):141–152. doi:10.1111/head.13682

 PubMed Web of Science ®Google Scholar

Färkkilä M, Diener HC, Gèraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a Phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405–413. doi:10.1016/S1474-4422(12)70047-9

 PubMed Web of Science ®Google Scholar

Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894–1904. doi:10.1093/brain/awz134

 PubMed Web of Science ®Google Scholar

Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36(9):887–898. doi:10.1177/0333102416653233

 PubMed Web of Science ®Google Scholar

Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114–125. doi:10.1177/0333102413500727

 PubMed Web of Science ®Google Scholar

Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–149. doi:10.1056/NEJMoa1811090

 PubMed Web of Science ®Google Scholar